Tyra Biosciences to Present at Upcoming Investor Conferences

27 Feb 2024
www.prnewswire.com
CARLSBAD, Calif., Feb. 27, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that company management will participate in the following investor conferences:
TD Cowen's 44th Annual Healthcare Conference, March 4-6th: Todd Harris, CEO of TYRA, will present a company overview on Wednesday, March 6, 2024, at 2:10 pm ET.  TYRA management will also participate in one-on-one meetings with investors during the conference.
Jefferies Biotech On the Bay Summit, March 11-13th: TYRA management will participate in one-on-one meetings with investors during the conference.
Barclays 26th Annual Global Healthcare Conference, March 12-14th: Todd Harris, CEO of TYRA, will participate in a fireside chat on Thursday, March 14th, 2024, at 8:00 am ET.  TYRA management will also participate in one-on-one meetings with investors during the conference.
A live and archived webcast of the Cowen presentation and Barclays fireside chat will be available via the
For Investors page on the Investor section of the TYRA website.
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. TYRA is based in Carlsbad, CA.
For more information about our science, pipeline and people, please visit  www.tyra.bio and engage with us on LinkedIn.
Contact:
Amy Conrad
[email protected]
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.